000 03816nam a22005415i 4500
001 978-1-4020-6554-5
003 DE-He213
005 20161121230758.0
007 cr nn 008mamaa
008 100301s2008 ne | s |||| 0|eng d
020 _a9781402065545
_9978-1-4020-6554-5
024 7 _a10.1007/978-1-4020-6554-5
_2doi
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a614.5999
_223
100 1 _aKhosravi-Far, Roya.
_eauthor.
245 1 0 _aProgrammed Cell Death in Cancer Progression and Therapy
_h[electronic resource] /
_cby Roya Khosravi-Far, Eileen White.
264 1 _aDordrecht :
_bSpringer Netherlands,
_c2008.
300 _aXIV, 356 p.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aAdvances in Experimental Medicine and Biology,
_x0065-2598 ;
_v615
505 0 _aCell Death: History and Future -- Caspase Mechanisms -- The Mitochondrial Death Pathway -- Apoptotic Pathways in Tumor Progression and Therapy -- Therapeutic Targeting of Death Pathways in Cancer: Mechanisms for Activating Cell Death in Cancer Cells -- Overcoming Resistance to Apoptosis in Cancer Therapy -- Trail Receptors: Targets for Cancer Therapy -- Rational Design of Therapeutics Targeting the BCL-2 Family: Are Some Cancer Cells Primed for Death but Waiting for a Final Push? -- Autophagy and Tumor Suppression: Recent Advances in Understanding the Link between Autophagic Cell Death Pathways and Tumor Development -- Regulation of Programmed Cell Death by the P53 Pathway -- Regulation of Programmed Cell Death by NF-?B and its Role in Tumorigenesis and Therapy -- Targeting Proteasomes as Therapy in Multiple Myeloma -- Histone Deacetylase Inhibitors: Mechanisms and Clinical Significance in Cancer: HDAC Inhibitor-Induced Apoptosis -- RNA Interference and Cancer: Endogenous Pathways and Therapeutic Approaches -- Cancer Stem Cells and Impaired Apoptosis.
520 _aProgrammed cell death (PCD) plays pivotal roles in tumor progression, cancer therapeutics and resistance of tumor cells to therapy. With the discovery of key mechanisms that are involved in mediating PCD and in promoting resistance to therapy, design of therapeutic approaches for promoting tumor-selective cell death has risen dramatically. With this book, we give a comprehensive overview of the mechanisms that are involved in mediating and regulating PCD in cancer. We also provide a detailed indication of the utility of PCD in cancer therapy. This book will be a valuable resource for researchers investigating the role of PCD in cancer and other diseases, researchers investigating the molecular mechanism of chemotherapeutic agents and drug-resistance in cancer and for physicians using chemotherapeutic agents. Additionally, this book will be a important educational source for PhD students specializing in cell biology, immunology and MD students interested in Oncology and Cancer Therapeutics.
650 0 _aMedicine.
650 0 _aCancer research.
650 0 _aImmunology.
650 0 _aMolecular biology.
650 0 _aOncology.
650 0 _aCell biology.
650 1 4 _aBiomedicine.
650 2 4 _aCancer Research.
650 2 4 _aCell Biology.
650 2 4 _aMolecular Medicine.
650 2 4 _aImmunology.
650 2 4 _aOncology.
700 1 _aWhite, Eileen.
_eauthor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781402065538
830 0 _aAdvances in Experimental Medicine and Biology,
_x0065-2598 ;
_v615
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-4020-6554-5
912 _aZDB-2-SBL
950 _aBiomedical and Life Sciences (Springer-11642)
999 _c503854
_d503854